Receptos Inc (RCPT) financial statements (2022 and earlier)
Company profile
| Business Address |
3033 SCIENCE PARK ROAD SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments, including: | 672 | 70 | ||
| Cash and cash equivalents | 458 | 24 | ||
| Short-term investments | 46 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 214 | 0 | ||
| Prepaid expense | 2 | |||
| Prepaid expense and other current assets | ✕ | 1 | ||
| Other undisclosed current assets | 2 | (0) | ||
| Total current assets: | 676 | 70 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 1 | 0 | ||
| Other noncurrent assets | 2 | |||
| Prepaid expense and other noncurrent assets | ✕ | 1 | ||
| Total noncurrent assets: | 2 | 1 | ||
| TOTAL ASSETS: | 678 | 71 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 29 | 15 | ||
| Accounts payable | 8 | 5 | ||
| Accrued liabilities | 16 | 8 | ||
| Employee-related liabilities | 4 | 2 | ||
| Debt | 1 | |||
| Deferred revenue and credits | 1 | |||
| Total current liabilities: | 29 | 16 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 4 | |||
| Long-term debt, excluding current maturities | 4 | |||
| Liabilities, other than long-term debt | 0 | |||
| Deferred revenue and credits | 0 | |||
| Total noncurrent liabilities: | 4 | |||
| Total liabilities: | 29 | 20 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 649 | 51 | ||
| Common stock | 0 | 0 | ||
| Additional paid in capital | 860 | 147 | ||
| Accumulated other comprehensive income (loss) | (0) | 0 | ||
| Accumulated deficit | (211) | (96) | ||
| Total stockholders' equity: | 649 | 51 | ||
| TOTAL LIABILITIES AND EQUITY: | 678 | 71 | ||
Income statement (P&L) ($ in millions)
| 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|
| Gross profit: | 6 | 5 | |
| Operating expenses | (117) | (53) | |
| Operating loss: | (112) | (48) | |
| Nonoperating income (expense) | (2) | 0 | |
| Investment income, nonoperating | 0 | 0 | |
| Foreign currency transaction loss, before tax | (3) | ||
| Other nonoperating income (expense) | 0 | (0) | |
| Interest and debt expense | (1) | (0) | |
| Net loss attributable to parent: | (115) | (48) | |
| Other undisclosed net loss available to common stockholders, basic | (2) | ||
| Net loss available to common stockholders, diluted: | (115) | (50) | |
Comprehensive Income ($ in millions)
| 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|
| Net loss: | (115) | (48) | |
| Comprehensive loss: | (115) | (48) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | 0 | |
| Comprehensive loss, net of tax, attributable to parent: | (115) | (48) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.